Loading...
No Data
Analyst Ratings for CRISPR Therapeutics
Over the past 3 months, 11 analysts have published their opinion on CRISPR Therapeutics (NASDAQ:CRSP) stock. These analysts are typically employed by large Wall Street banks and tasked with understand
CRISPR Therapeutics hires Chief Medical Officer
Phuong Khanh Morrow has been appointed as Chief Medical Officer at biopharmaceutical company CRISPR Therapeutics (NASDAQ:CRSP).Morrow assumes the role on May 23, 2022 and will oversee the firm's globa
CRISPR Therapeutics analyst ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/17/2022 2.83% Citigroup $64 → $53 Maintains Neutral 05/13/2022 136.71% Needham $170 → $122 Maintains Bu
Citigroup Maintains Neutral on CRISPR Therapeutics, Lowers Price Target to $53
Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral and lowers the price target from $64 to $53.
Crispr Therapeutics Price Target Cut to $53.00/Share From $64.00 by Citigroup
Crispr Therapeutics Is Maintained at Neutral by Citigroup
CRISPR Therapeutics (CRSP) Stock: $53 Price Target From Citi
The shares of CRISPR Therapeutics (NASDAQ: CRSP) have received a $53 price target from Citi. These are the details. The shares of CRISPR Therapeutics (NASDAQ: CRSP) have received a $53 price target f
Citigroup Adjusts Price Target on CRISPR Therapeutics to $53 From $64, Maintains Neutral Rating
06:04 AM EDT, 05/17/2022 (MT Newswires) -- CRISPR Therapeutics AG (CRSP) has an average rating of outperform and price targets ranging from $52 to $220, according to analysts polled by Capital IQ. (MT
Evercore ISI Keeps a Buy Rating on Crispr Therapeutics AG (CRSP)
In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), with a price target of $66.00. The company's shares closed la
Crispr Therapeutics appoints Morrow as CMO
CRISPR Therapeutics (CRSP) announced the appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer, CMO, effective May 23, 2022. Dr. Morrow brings more than a decade of leadership exper